353 - QUOI DE NEUF SUR LES ANTIPLAQUETTAIRES EN 2025?

Saturday, October 25, 2025

3:15pm - 4:15pm ET

Room:207

Target Audience: Trainee (clinical), Structural Interventional Team Members, Clinical cardiologists

Co-Chair(s)

Samer Mansour, MD FRCPC (he/him/his)

Cardiologist
CHUM
CHUM
JM

Josée Morin, MD

Presenter(s)

MN

Michel Nguyen, MD

Cardiologist
Centre Hospitalier Universitaire de Sherbrooke
Christine Pacheco, MD MSc

Cardiologist
Hôpital Pierre Boucher
Université de Montréal
Brian Potter, MDCM SM

Interventional cardiologist
Centre hospitalier de l'Université de Montréal
Université de Montréal
Jean-François Tanguay, MD

Director, Interventional Cardiology Division, Montreal Heart Insitute,
University of Montreal
Université de Montréal

Early Career(s)

Vartan Mardigyan, MD

Assistant Professor
CCS
McGill University

Trainee(s)

MB

Marie-Christine Blais, MD

Cardiologist
Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval
Kevin Haddad, MD

Adult Cardiology Resident
University of Montreal

Moderator(s)

Samer Mansour, MD FRCPC (he/him/his)

Cardiologist
CHUM
CHUM
JM

Josée Morin, MD

Planning Committee Member(s)

MB

Marie-Christine Blais, MD

Cardiologist
Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval
RE

Richard Essiambre, MD

MD
CHRS
Kevin Haddad, MD

Adult Cardiology Resident
University of Montreal
Samer Mansour, MD FRCPC (he/him/his)

Cardiologist
CHUM
CHUM
Vartan Mardigyan, MD

Assistant Professor
CCS
McGill University
Brian Potter, MDCM SM

Interventional cardiologist
Centre hospitalier de l'Université de Montréal
Université de Montréal

Workshop Description: This workshop is intended to be presented in French, as part of the partnership between the Association des Cardiologues du Québec and the CCC.
The usage of antiplatelets remains a challenge in the real life. Different clinical situations dictate different choice of antiplateltes. The usage of sigle and dual antiplatelets will be discussed in patients with chronic or acute coronary syndrome. The workshop aims to enhance the knowledge level and address the learning needs in the field of antiplatelets. Each presentation will begin with a clinical case presentation focusing on patient's indication, type of treatment medical, PCI or CABG. This workshop provides a great opportunity for members from different affiliations to collaborate including clinical and interventional cardiologists. Presentations will cover the usage of oral and intravenous antiplatelet mainly in special subgroups of patients manily those at high risk of ischemic or bleeding complications.
The ACQ CME committee planned this workshop consisting of community and academic cardiologists, interventional cardiologists and cardiology trainees with diverse practices and experiences across Quebec. The ACQ CME ensures an objective and balanced representation of the topic " Atelier conjoint ACQ-CCC: Nouveautés sur les antiplaquettaires ", free of third-party influence or support. Selected speakers from across Quebec represent diversity in gender, generation and geography.

Learning Objectives:

At the end of this session participants will be able to:

optimizing antiplatelet management in ACS, by assessing the indication for dual therapy in the emergency room;
define the indications for an intravenous P2Y12 inhibitor, depending on the clinical context; and
adapt antiplatelet management in patients at high risk of bleeding and in patients treated medically, balancing thrombotic prevention and bleeding risk